Barrington Research Maintains Outperform Rating for LeMaitre Vascular: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Barrington Research has maintained its Outperform rating for LeMaitre Vascular (NASDAQ:LMAT) and increased its price target from $66.00 to $69.00. Following this announcement, LMAT shares have risen by 3.28% to $64.15. The new price target suggests a potential upside of 7.56%. LeMaitre Vascular specializes in manufacturing and distributing medical devices for peripheral vascular disease treatment, with the majority of its revenue generated in the United States.
February 28, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barrington Research maintains Outperform rating for LMAT, raising price target to $69. Shares have increased by 3.28% to $64.15, indicating positive market response.
The maintenance of an Outperform rating and the increase in price target by Barrington Research are strong indicators of confidence in LeMaitre Vascular's future performance. The subsequent rise in share price reflects a positive market response, suggesting short-term bullish sentiment among investors.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100